Hookipa Pharma — Merger or Acquisition (January 2025)
44 slides from Hookipa Pharma's merger presentation, Jan 2, 2025
Slide 1: Next-generation Immunotherapies for the Treatment of Cancer and Other Serious Diseases
January 2025 NASDAQ: HOOK HOOKIPA Pharma Next - generation Immunotherapies for the Treatment of Cancer and Other Serious Diseases
Slide 2: Forward-looking statements
This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including statements regarding HOOKIPA's expectations regarding the terms, benefits, impacts and timing of the proposed combination (the "Proposed Combin
Slide 3: Important Information
Important Information This presentation relates to a proposed business combination (the "Proposed Combination") of HOOKIPA Pharma Inc . (“HOOKIPA”) and Poolbeg Pharma plc (" Poolbeg ”) . If a firm offer is made or the parties otherwise agree to binding terms with respect to the Proposed Combination,
Slide 4: Participants in the Solicitation
Participants in the Solicitation HOOKIPA, Poolbeg , and their respecitve directors and executive officers may be deemed “participants” in any solicitation of proxies from HOOKIPA's shareholders with respect to the Proposed Combination . Information regarding the identity of HOOKIPA's directors and e
Slide 5: Merger Transaction Overview
Merger Transaction Overview 5 • Proposed all stock transaction where HOOKIPA acquires Poolbeg Pharma plc • HOOKIPA remains TopCo with existing Nasdaq listing • Concurrent Financing: Private placement of up to approximately $30M to be funded into HOOKIPA immediately following transaction close • Impl
Slide 6: HOOKIPA-Poolbeg Merger Would Diversify Clinical Pipeline and Bolsters Near-Term Catalysts
HOOKIPA - Poolbeg Merger Would Diversify Clinical Pipeline and Bolsters Near - Term Catalysts 6 Combined Leadership Team Bolsters Near - Term Clinical Data Catalysts Diversifies Pipeline Next - generation cancer immunotherapy portfolio led by multi - KRAS - targeting HB - 700 and Phase 2 - ready sma
Slide 7: HOOKIPA: Immunotherapy Focused Programs & Pipeline Opportunities
HOOKIPA: Immunotherapy Focused Programs & Pipeline Opportunities 7 Infectious Disease Immunotherapy for HBV Immunotherapy for HIV HB - 400 HB - 500 Oncology HB - 700 POLB 001 Next - generation multi - KRAS targeting cancer immunotherapy with blockbuster potential Potentially breakthrough orally deli
Slide 8: Differentiated Immunotherapies in Well-Defined Populations with Large Market Potential
HOOKIPA is Advancing Differentiated Immunotherapies in Well - Defined Populations with Large Market Potential 8 GLP - 1R: Glucagon - like peptide - 1 receptor. POC: Proof of concept; 1: HB - 400 (GS - 2829): https://clinicaltrials.gov/study/NCT05770895?term=GS - 2829&rank=1 ; 2: HB - 500 (GS - 6779)
Slide 9: Proposed Team with Proven Execution and Operational Leadership
Proposed Team with Proven Execution and Operational Leadership 9 Mark Winderlich , PhD Chief Development Officer Ian O’Connell Chief Financial Officer, Poolbeg Co - Founder John McEvoy Chief Legal Officer Malte Peters, MD, PhD Chief Executive Officer Cathal Friel Executive Chairman, Poolbeg Co - Fou
Slide 10: HOOKIPA Has a Diversified Core Immunotherapy Pipeline
Key Milestone Phase 3 Phase 2 Phase 1 Preclinical Indication Modality Product Oncology Programs FPD in Phase 1 trial expected mid - 2025 KRAS Mutated T umors Next - generation immunotherapy HB - 700 FPD in Phase 2 trial expected H2 2025 Immunotherapy - induced CRS p38 MAPK inhibitor POLB 001 Partner
Slide 11: HOOKIPA Pipeline has Additional Partnership Opportunities
Key Milestone Phase 3 Phase 2 Phase 1 Preclinical Indication Modality Product Additional Programs Final Phase 2 data expected H2 2025 HPV16+ HNSCC Next - generation immunotherapy Eseba - vec (HB - 200) Topline POC data expected H1 2026 Obesity and diabetes GLP - 1R agonist GLP - 1 Program Potential
Slide 12: HOOKIPA's Next-Gen Vaccine Platform Designed to Supercharge Immunity
HOOKIPA’s Next - Gen Vaccine Platform Designed to Supercharge Immunity 1 - 4 T cell activation platform based on work of Nobel laureate and HOOKIPA co - founder Rolf Zinkernagel 5 1: Lauterbach H, et al. Front Oncol. 2021;11:732166; 2: Fu S, et al. ASCO 2022. Abstract 2517; 3: Bonilla WV, et al. Cel
Slide 13: HB-700: Next-generation multi-KRAS targeting cancer immunotherapy
13 HB - 700 Next - generation multi - KRAS targeting cancer immunotherapy with blockbuster potential
Slide 14: KRAS is the Most Prevalent Oncogenic Driver
KRAS is the Most Prevalent Oncogenic Driver NSCLC: Non - small cell lung cancer. CRC: colorectal cancer. PDAC: pancreatic ductal adenocarcinoma Source: Trinity Life Sciences, Kantar, World Cancer Research Fund 14 Targeting KRAS has been challenging due to lack of activity, poor selectivity or treatm
Slide 15: HB-700: A Novel Multi-KRAS Mutant Targeting Cancer Immunotherapy
HB - 700: A Novel Multi - KRAS Mutant Targeting Cancer Immunotherapy Designed for uniquely strong anti - tumor T cell activation 15 Large addressable populations in NSCLC, CRC and PDAC KRAS mutation specific T cell activation in humanized mice; preclinical profile supports diverse combinations Dose
Slide 16: HB-700: Open-Label Phase 1/2 in Metastatic KRAS-Mutated NSCLC
HB - 700: Open - Label Phase 1/2 in Metastatic KRAS - Mutated NSCLC Clinical POC in NSCLC followed by expansion in related indications HLA: human leukocyte antigens. RP2D: Recommended Phase 2 dose. ORR: Overall response rate. DCR: Disease control rate. DoR : Duration of Response. PFS: Progression fr
Slide 17: HB-700 KRAS Immunotherapy has Potential for $1.5B Peak Worldwide Net Sales
PDAC CRC NSCLC 1L Addressable Patient Population (US+EU5) Unmet Need Tumor immune microenvironment HB - 700 KRAS Immunotherapy has Potential for $1.5B Peak Worldwide Net Sales* Across 1L NSCLC, CRC and PDAC, if approved Additional expansion opportunities in 2L and neoadjuvant/adjuvant for locally ad
Slide 18: HB-700 Potential to Combine with Diverse Approved and Emerging Therapies
HB - 700 Potential to Combine with Diverse Approved and Emerging Therapies 18 Checkpoint Inhibitor Combination clinical POC on combination with anti - PD1 and eseba - vec 1 KRAS Inhibitor Combination potential to work synergistically with immunotherapy likely by remodelling the TME making it more su
Slide 19: POLB 001: Oral p38 MAPK inhibitor to prevent cancer immunotherapy-induced CRS
19 POLB 001 Potentially breakthrough orally delivered p38 MAPK inhibitor to prevent cancer immunotherapy - induced CRS
Slide 20: CRS Associated with Immunotherapies is a High Unmet Need
CRS Associated with Immunotherapies is a High Unmet Need Effective prophylaxis represents a >$10B market opportunity 20 Cytokine Release Syndrome (CRS) A s evere , potentially life - threatening side effect of cancer immunot hera pies No a pproved therapies for prevention Approved options for CRS ma
Slide 21: POLB 001: Potential to Make Immunotherapies Safer & More Accessible
POLB 001: Potential to Make Immunotherapies Safer & More Accessible *CRS score is a 0 - 4 system of physical observations where 0 is normal and 4 is moribund. MAPK: Mitogen Activated Protein Kinase. TNF: Tumour necrosis factor, IL - 6: Interleukin - 6 21 Selective p38 MAPK Inhibitor Strong P reclini
Slide 22: LPS Human Challenge: Potent Inhibition of Excessive Inflammation
LPS Human Challenge: Potent Inhibition of Excessive Inflammation Supportive of potential of POLB 001 as a prophylactic for cancer immunotherapy - induced CRS 22 Trial design : Single site, randomized placebo controlled LPS challenge trial. Healthy males administered BID oral POLB 001 or vehicle onl
Slide 23: Planned POLB Phase 2a Investigator Initiated Trial for Prevention of CRS
Planned POLB 001 Phase 2a Investigator Initiated Trial for Prevention of CRS in R/R Multiple Myeloma Patients Receiving Bispecific Ab Expect FPD in Phase 2 trial H2 2025 with topline data expected in H2 2026 23 Phase 2a IIT *Clinical trial collaboration and supply agreements with a large pharma comp
Slide 24: CRS Preventative Therapy: >$10B US Market Opportunity
CRS Preventative Therapy: > $ 10B US Market Opportunity 3 A significant opportunity exists for POLB 001 as an adjunct therapy to bispecific and CAR T treatment 24 1 st , 2 nd and 3 rd line+ MM and DLBCL patients in the US and EU5, receive CAR T cell and bispecific antibody therapy 1 An effective pri
Slide 25: Gilead Strategic Partnerships HB-400 and HB-500
25 Gilead Strategic Partnerships HB - 400 and HB - 500
Slide 26: Gilead–HOOKIPA: Aim to Develop Functional Cures for HBV and HIV
Gilead – HOOKIPA: Aim to Develop Functional Cures for HBV and HIV E ntered into a strategic collaboration in June 2018 26 HB - 400 For the treatment of Hepatitis B A lternating , two - vector non - replicating arenaviral HBV immunotherapy High Potential candidate in Gilead’s efforts to develop a cur
Slide 27: HOOKIPA's Immunotherapies are a Key Partner in Gilead's HBV & HIV Cure Programs
HOOKIPA’s Immunotherapies are a Key Partner in Gilead’s HBV & HIV Cure Development Programs Using combination strategies and novel mechanisms with the goal to drive viral suppression and durable immunity 1 - 4 bNAbs : broadly neutralizing antibodies. siRNA: small interfering ribonucleic acid. ASO: A
Slide 28: HOOKIPA-Gilead Partnership Offers Significant Revenue Potential
HB - 500 for HIV HOOKIPA - Gilead Partnership Offers Significant Revenue Potential 28 HB - 400 for HBV Gilead responsible for clinical development Next milestone payment: start of Phase 2 HOOKIPA Responsibilities • Vector design • Manufacturing and supply of clinical material Terms • $185M potential
Slide 29: Additional Programs: Eseba-vec (HB-200), Oral GLP-1, AI Programs
29 Additional Programs Eseba - vec (HB - 200), Oral GLP - 1, AI Programs
Slide 30: Eseba-vec (HB-200) in Recurrent/Metastatic HPV16+ HNSCC
Eseba - vec (HB - 200) in Recurrent/Metastatic HPV16+ HNSCC Strong scientific thesis with mature Phase 2 data and POC in combination with checkpoint inhibitors ORR: Objective response rate. SOC: Standard of care (pembrolizumab monotherapy). HNSCC: Head and Neck Squamous Cell Carcinoma . P OC: Proof
Slide 31: Additional Pipeline Programs in Large Market Opportunities
GLP - 1 Program – Oral GLP - 1R agonist Additional Pipeline Programs in Large Market Opportunities 31 RSV and Influenza Preclinical assets Computational Platform Opportunity 2 Integrates proprietary m ulti - parametric clinical data to identify novel host response targets Discussions ongoing in resp
Slide 32: Combined Company and Financial Overview
32 Combined Company and Financial Overview
Slide 33: HOOKIPA: Global Company with Strong Patents and Cash Runway
HOOKIPA: Global Company with Strong Patents and Cash Runway 33 Offering Size Up to approximately US$30M Expected to be Debt Free with Cash Runway Through YE 2026* Combined company expected to have operations in EU, UK & US Robust patent portfolio covering: • Platform patents • Product - specific pat
Slide 34: Clinical Milestones in High Interest Areas Over the Next Months
Clinical Milestones in High Interest Areas Over the Next 24 Months Cash runway expected to be extended through YE2026* including HB - 700, POLB 001 & HB - 500 milestones IIT: Investigator Initiated Trial. FPI: First Patient In. GLP - 1: Glucagon - like peptide - 1. POC: Proof of Concept 1: Managemen
Slide 35: Well-Positioned to Advance Next-Generation Immunotherapies for Cancer and Serious Diseases
Well - Positioned to Advance Next - Generation Immunotherapies for Cancer and Serious Diseases 35 Diverse Pipeline Merger would add Phase 2 - ready POLB 001 to expand immunotherapy portfolio in oncology Unprecedented T Cell Activation Antigen - specific T cell activation designed to produce durable,
Slide 36: Appendix
117 Appendix
Slide 37: HOOKIPA-Poolbeg Merger Brings a New Management Team
HOOKIPA - Poolbeg Merger Brings a New Management Team with a Track Record of Delivering Shareholder Returns DLBCL: diffuse large B cell lymphoma. EB: epidermolysis bullosa. FL: Follicular lymphoma. MF: myelofibrosis. PI3K: Phosphoino sit ide 3 - kinases. 1st L: first line. 2nd L: second line. 37 • M
Slide 38: HB-700 Preclinical Proof of Concept in Humanized Mice
HB - 700 Preclinical Proof of Concept: Highly Immunogenic with Potent Target Cell Killing in Humanized Mice 38 KRAS mut specific T cells exhibit a polyfunctional profile KRAS mut specific T cells are functional and specifically kill target cells WT G12V G12D G12D WT G12V G12D 1 HLA - A*11:01 transge
Slide 39: POLB 001: An Oral p38 MAPK Inhibitor That Selectively Targets Key Inflammatory Pathways
POLB 001: An Oral p38 MAPK Inhibitor That Selectively Targets Key Inflammatory Pathways Without Broad Immunosuppression Phase 2 ready asset with a comprehensive pre - clinical and clinical data package AE = adverse event. FIH = First in human; SAE = Serious adverse events; ECG = Electrocardiogram 39
Slide 40: POLB 001: Benefit in Treatment of LPS-Induced Inflammation
POLB 001: Benefit in Treatment of LPS - Induced Inflammation Randomized, double - blind, placebo - controlled, inflammatory challenge trial in healthy volunteers 40 Intravenous LPS challenge • Bloods (cytokines, vascular markers, CRP) • Ex - vivo LPS response • Safety & tolerability (inc. vital sign
Slide 41: POLB 001 is Designed to Address a High Unmet Medical Need
POLB 001 is Designed to Address a High Unmet Medical Need Effective prevention of CRS by POLB 001 may enable broader access to cancer immunotherapies DLBCL: Diffuse Large B - Cell Lymphoma. KOL: Key opinion leader. MM: Multiple Myeloma. 1. Datamonitor Healthcare. Forecast: Diffuse Large B - Cell Lym
Slide 42: Eseba-vec: Synergistic Activity in Combination with Pembrolizumab
Eseba - vec : Synergistic Activity in Combination with Pembrolizumab Eseba - vec (HB - 200) is a next - generation immunotherapy targeting HPV+ cancers Source: Harrington updated data KEYNOTE - 048 JCO 2023 (median follow - up was 45.0 months, n = 882); Phase 1/2 data as of 30 - Sep - 20 24 cut - of
Slide 43: Eseba-vec Exhibits Promising Preliminary PFS In 1L HPV+ R/M HNSCC
Eseba - vec Exhibits Promising Preliminary PFS In 1L CPS ≥ 20 HPV+ R/M H&NSCC 43 PFS: Progression Free Survival; Source: Phase 1/2 data as of 30 - Sep - 2024 cut - off, presented at 2024 SITC conference; Efficacy da taset includes 27 patients with minimum 4.5 months of follow - up time after first d
Slide 44: Eseba-vec Has Broad Potential Across Multiple HPV16+ Cancers
Eseba - vec Has Broad Potential Across Multiple HPV16+ Cancers Up to ~20,000 US patients and ~39,000 patients globally 44 *Assuming full expansion beyond initial label (HPV16+ HNSCC and anogenital tumors) E ~17.5 - 20K patients D ~10 - 13K patients C ~4.5 - 8K patients B ~3 - 5.5K patients A ~1.5 -
HOOKIPA Pharma — Merger or Acquisition (January 2025) on 6ix